Abstract
Despite its efficacy in many cases, the drug treatment of schizophrenia remains problematic. A substantial proportion of patients do not improve, and many others suffer from unpleasant side-effects. In this review, Gavin Reynolds describes the new approaches to antipsychotic drug development that attempt to address these problems, and relates some of these approaches to growing evidence for neuronal pathology in the brain in schizophrenia.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use*
-
Dopamine Antagonists
-
Humans
-
Narcotic Antagonists
-
Receptors, Dopamine / metabolism
-
Receptors, Glutamate
-
Receptors, Neurotransmitter / antagonists & inhibitors
-
Receptors, Neurotransmitter / metabolism
-
Receptors, Opioid / metabolism
-
Receptors, Serotonin / metabolism
-
Receptors, sigma
-
Schizophrenia / drug therapy*
-
Serotonin Antagonists
Substances
-
Antipsychotic Agents
-
Dopamine Antagonists
-
Narcotic Antagonists
-
Receptors, Dopamine
-
Receptors, Glutamate
-
Receptors, Neurotransmitter
-
Receptors, Opioid
-
Receptors, Serotonin
-
Receptors, sigma
-
Serotonin Antagonists